Article
Resistance to the KRASG12D Inhibitor MRTX1133 Is Associated with Increased Sensitivity to BET Inhibition.
Molecular cancer therapeutics - 1 Jun 2026
Principe Daniel R, Becker Jeffrey H, Metropulos Anastasia E, Marinelarena Alejandra M, Pham Thao D, Aissa Alexandre F, Munshi Hidayatullah G
Abstract excerpt
As many as 90% of human pancreatic ductal adenocarcinoma (PDAC) tumors harbor gain-of-function mutations in the KRAS oncogene. Recently, inhibitors of the most common KRAS mutation, KRASG12D, have entered the clinical arena. However, early evidence suggests that as monotherapy, KRASG12D inhibitors such as MRTX1133 at best provide brief periods of disease stabilization. Hence, there is a growing interest in...
Topics
Join the communities discussing this publication.